Gland Pharma Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Chemplast Sanmar Ltd, Mangalore Refinery And Petrochemicals Ltd, K E C International Ltd, Alkyl Amines Chemicals Ltd are among the other stocks to see a surge in volumes on NSE today, 05 November 2024.

Gland Pharma Ltd recorded volume of 45.95 lakh shares by 14:14 IST on NSE, a 42.24 times surge over two-week average daily volume of 1.09 lakh shares. The stock gained 11.76% to Rs.1,800.30. Volumes stood at 88189 shares in the last session.

Chemplast Sanmar Ltd recorded volume of 39.86 lakh shares by 14:14 IST on NSE, a 24.06 times surge over two-week average daily volume of 1.66 lakh shares. The stock gained 2.20% to Rs.485.65. Volumes stood at 1.49 lakh shares in the last session.

Mangalore Refinery And Petrochemicals Ltd notched up volume of 178.29 lakh shares by 14:14 IST on NSE, a 8.33 fold spurt over two-week average daily volume of 21.41 lakh shares. The stock rose 10.30% to Rs.162.78. Volumes stood at 14.78 lakh shares in the last session.

K E C International Ltd recorded volume of 19.48 lakh shares by 14:14 IST on NSE, a 7.12 times surge over two-week average daily volume of 2.73 lakh shares. The stock lost 1.29% to Rs.956.20. Volumes stood at 4.88 lakh shares in the last session.

Alkyl Amines Chemicals Ltd notched up volume of 2.24 lakh shares by 14:14 IST on NSE, a 5.98 fold spurt over two-week average daily volume of 37423 shares. The stock rose 2.28% to Rs.2,153.95. Volumes stood at 39333 shares in the last session.

Powered by Capital Market - Live News

Chemplast Sanmar Ltd, Hatsun Agro Product Ltd, ABB India Ltd, Bata India Ltd are among the other stocks to see a surge in volumes on BSE today, 05 November 2024.

Gland Pharma Ltd saw volume of 47247 shares by 10:47 IST on BSE, a 10.69 fold spurt over two-week average daily volume of 4421 shares. The stock increased 9.75% to Rs.1,766.80. Volumes stood at 6858 shares in the last session.

Chemplast Sanmar Ltd recorded volume of 36259 shares by 10:47 IST on BSE, a 5.59 times surge over two-week average daily volume of 6484 shares. The stock gained 4.70% to Rs.497.00. Volumes stood at 7142 shares in the last session.

Hatsun Agro Product Ltd witnessed volume of 12872 shares by 10:47 IST on BSE, a 4.76 times surge over two-week average daily volume of 2704 shares. The stock increased 9.17% to Rs.1,160.15. Volumes stood at 9414 shares in the last session.

ABB India Ltd recorded volume of 37866 shares by 10:47 IST on BSE, a 4.45 times surge over two-week average daily volume of 8510 shares. The stock lost 3.97% to Rs.7,069.90. Volumes stood at 9507 shares in the last session.

Bata India Ltd notched up volume of 43257 shares by 10:47 IST on BSE, a 3.69 fold spurt over two-week average daily volume of 11733 shares. The stock rose 0.59% to Rs.1,344.75. Volumes stood at 15468 shares in the last session.

Powered by Capital Market - Live News

On consolidated basis, the firm’s net profit declined 15.74% to Rs 163.53 crore on 2.36% to Rs 1,405.83 crore in Q2 FY25 over Q2 FY24.

Profit before tax (PBT) stood at Rs 256.78 crore, down 11.42% as compared with Rs 289.89 crore in second quarter of FY24.

For Q2 of FY25, EBITDA was Rs 296.1 crore, registering de-growth of 8%. EBITDA margin reduced from 21% to 23% during the quarter.

Revenue from US market stood at Rs 754.7 crore (up 3% YoY), revenue Europe was at Rs 245.9 crore (down 1% YoY), Canada, Australia and New Zealand stood at Rs 51.5 crore (up 45% YoY) while revenue from India was at Rs 87.4 crore and Rest of the world was at Rs 266.3 crore during the period under review.

Total capex incurred during the quarter was Rs 103.7 crore.

R&D expenses stood at Rs 49.3 crore in Q2 of FY25, (4.6% of revenue).

Cenexi’s gross profit shed 15% YoY to Rs 234.7 crore and revenue from operations decreased 5% YoY to Rs 339.9 crore during the quarter.

On outlook front, the company said that despite the near-term headwinds, it continued to strive to achieve short-term outlook: a positive EBITDA for Q4 of FY25. It maintains goal of a positive EBITDA for the next fiscal year, driven by an increase in revenue above the €200 million threshold.

Srinivas Sadu, executive chairman and CEO of Gland Pharma, said, “We had a good first half of 2025 and are on course to achieve our outcomes for the full year. This quarter, we reported Rs 14,058 million in revenue and Rs 2,961 million in EBITDA, representing a 21% EBITDA margin. Although our overall EBITDA margin was affected by Cenexi, our base business maintained a steady 34% EBITDA margin. Our core regulated markets, particularly the United States, continue to perform well. Our overall performance is in line with expectations. Looking ahead, we remain focused on our strategic priorities, which include entering new markets and building a solid foundation for future growth.”

Gland Pharma is one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered Heparin technology in India.

Powered by Capital Market - Live News

Net profit of Gland Pharma declined 15.74% to Rs 163.53 crore in the quarter ended September 2024 as against Rs 194.08 crore during the previous quarter ended September 2023. Sales rose 2.36% to Rs 1405.83 crore in the quarter ended September 2024 as against Rs 1373.42 crore during the previous quarter ended September 2023.

Powered by Capital Market - Live News